Challenges in Developing Effective Treatments for Hepatitis Delta Virus Infection
Despite significant progress, the Hepatitis Delta Virus (HDV) Infection Market faces challenges related to drug development. HDV’s complex life cycle and reliance on HBV complicate therapeutic targeting. Interferon therapy remains the only FDA-approved treatment, but its limitations prompt the need for better options.
Clinical trials for new drugs face hurdles including patient recruitment and managing side effects. High research and development costs also impact affordability and accessibility. Addressing these challenges through innovation and collaborative research is critical for sustained market growth.
1 View